Obesity is a metabolic disease that affects all ages; it is considered life-threatening condition as it leads to fatal complications such as; cardiovascular diseases and diabetes. The therapeutic options include; life-style modifications, pharmacotherapy intervention, and surgical intervention. Bariatric surgery (BS) is considered as the most effective option among the others for its rapid weight loss, maintaining the lost mass, and improving the quality of life of the patients. Nevertheless, BS leads to severe changes in the bioavailability of medications, especially for chronic diseases, which may reach to limit where the patient's life endangers. Recently, pharmaceutical formulations had developed several methods to improve the drug bioavailability of drugs though the implying of nanotechnology. Nonotechnology is responsible for reducing the size of the drugs to the nano range (<1000 nm), which increase the drug surface area, dissolution, absorption, and, most importantly, the bioavailability of these drugs. It is believed that BS malabsorption and drugs bioavailability problems can be solved using nanotechnology for its advantages in overcoming BS complications.

肥胖是一种影响所有年龄段的代谢性疾病；它被认为是威胁生命的状况，因为它会导致致命的并发症，例如；心血管疾病和糖尿病。治疗选择包括：生活方式改变，药物治疗干预和外科手术干预。减肥手术（BS）被认为是最有效的选择，因为它可以快速减肥，保持体重减轻并改善患者的生活质量。但是，BS会导致药物的生物利用度发生严重变化，尤其是对于慢性疾病，这种变化可能会限制患者生命的危险。近来，尽管暗示了纳米技术，药物制剂已经开发了几种方法来改善药物的药物生物利用度。Nonotechnology负责将药物的尺寸减小至纳米范围（<1000 nm），这会增加药物的表面积，溶解，吸收以及最重要的是这些药物的生物利用度。人们认为，使用纳米技术可以解决BS吸收不良和药物生物利用度的问题，因为它具有克服BS并发症的优势。